Dutasteride vs finasteride for hair loss: verify approval, route, and product

For hair loss in the United States, finasteride 1 mg has an FDA-approved indication for male-pattern hair loss in men, while FDA-approved dutasteride products are labeled for benign prostatic hyperplasia; using dutasteride for hair loss is off label. That distinction does not choose a medicine: compare the exact oral or compounded topical product, diagnosis, population, evidence, systemic and contact exposure, contraindications, adverse effects, fertility and pregnancy precautions, monitoring, and stop plan.¹²³⁴

The comparison should never begin and end with “dutasteride blocks more DHT” or an online hair-count chart.

Put formulation beside every ingredient

“Prescription strength,” “custom,” “dermatologist formulated,” and “uses FDA-approved ingredients” do not establish approval of the finished product.

Approval status and prescribing evidence are separate

The Propecia label defines a finasteride product, intended population, use, contraindications, warnings, and adverse reactions.¹ The Avodart approval record anchors dutasteride to a different labeled job.² A licensed prescriber may use an approved drug off label when medically appropriate, but the clinic should say so and explain the supporting evidence and uncertainties.

Ask the prescriber to write:

• the hair-loss diagnosis and evidence for it;
• why this molecule, formulation, and route are proposed;
• whether use is labeled or off label;
• what benefit endpoint and time point will be assessed;
• what risks, alternatives, and no-treatment option were discussed; and
• who handles symptoms, fertility questions, and stopping.

An off-label use is not automatically experimental or improper. It is also not FDA-approved simply because studies exist.

Comparative reviews need like-for-like reading

A 2024 systematic review compared finasteride and dutasteride across nine androgenetic-alopecia studies: four randomized controlled trials, one single-arm trial, two prospective cohorts, and two retrospective cohorts. Seven studies enrolled only men; two included women.³ Its conclusions across varied doses, populations, and designs are not a personalized prescription or proof that every studied dose and formulation has U.S. approval.

For any superiority claim, inspect:

1. randomized head-to-head versus indirect comparison;
2. oral versus topical route;
3. men, women, age range, diagnosis, and baseline severity;
4. dose and treatment duration;
5. photographic, hair-count, clinician, or patient-reported endpoint;
6. absolute effect, uncertainty, attrition, and missing data;
7. adverse-event collection and follow-up after stopping; and
8. sponsor and conflicts.

A statistically different hair count may not match the outcome a patient values. A short trial may not capture later adverse effects or durability.

Keep topical compounds in a separate product lane

FDA says there is no FDA-approved topical finasteride and has warned that compounded topical products have generated reports of systemic adverse events and can create transfer exposure.⁴ A topical offer therefore needs its own pharmacy, formula, delivered amount, applicator, contact controls, and refill-change record; the compounded-topical-finasteride guide holds the full verification framework.

The Propecia tablet label separately instructs people who are or may become pregnant not to handle crushed or broken tablets because finasteride can be absorbed through the skin and may pose a risk to a male fetus.¹ FDA’s compounded-topical alert addresses transfer precautions for that different product lane.⁴ Use the instructions for the exact finished or compounded product rather than blending the two warnings.

Fertility and sexual symptoms need a baseline

Before treatment, document reproductive goals, sexual symptoms, semen or fertility evaluation when clinically relevant, mood and neurologic symptoms, breast symptoms, current medicines and supplements, and previous hair treatments. This does not imply that each person needs every test; it prevents a later change from having no baseline or owner.

Do not reduce counseling to a disputed percentage on social media. Ask how trials defined and elicited adverse events, for how long, and what the product label and current evidence say. A clinic should provide a private, non-dismissive route to report sexual, reproductive, mood, allergic, or other concerns.

Hair photography should be measurement, not marketing

Use standardized hair length, styling, washing interval, lighting, camera, angle, part, and scalp region. Record concurrent minoxidil, procedures, supplements, illness, stress, and hairstyle changes. Define the assessment time and what result would justify continuing.

Selected before-and-after images cannot show the denominator or distinguish medication effect from lighting, fiber products, hairstyle, natural fluctuation, or combined therapy. The oral-versus-topical minoxidil guide helps keep concurrent products visible.

Leave with one reconciled product record

1. Confirm the diagnosis. Document the hair-loss pattern, history, examination, relevant alternatives, and clinician responsible for other possible causes.
2. Identify the product and status. Match ingredient, route, manufacturer or compounding pharmacy, strength, delivered amount, label, and labeled or off-label use.
3. Normalize the evidence. Separate direct from network comparisons and match dose, route, population, endpoint, duration, attrition, and harms.
4. Plan exposure and counseling. Address overlapping products, transfer, pregnancy, fertility goals, sexual and mood symptoms, procedures, and other medicines.
5. Define review and stopping. Use standardized outcomes, a review date, symptom contact, refill controls, and a clinician-owned exit plan.

The decisive question is: “What exact oral or topical product is being offered, what is its U.S. approval status for this use, and what evidence and monitoring match this person and formulation?”